This medication conflict checker helps people with acute myeloid leukemia find out whether the medicines they are taking now could affect clinical trial eligibility. Select one or more medications below to screen active AML trials for potential conflicts.
AML trials are unusual in that many enroll only at a fixed point in treatment: before the first dose, at first relapse, or during remission. The medicines that most often decide eligibility are the ones used to treat the leukemia itself: whether you have had venetoclax, a hypomethylating agent, a FLT3 inhibitor, an IDH inhibitor or a menin inhibitor, and how recently. Supportive medicines such as antifungals and antibiotics rarely exclude you, but a few interact with study drugs and may need to be changed.
Venetoclax and Hypomethylating Agents
Venclexta, Vidaza (azacitidine), decitabine, Inqovi, Onureg — frontline trials of new combinations usually require that you have never received venetoclax or a hypomethylating agent for AML, and relapse trials often sort people by whether the leukemia progressed on venetoclax. Most protocols ask for a washout of 14 days or 5 half-lives from the last dose, and hydroxyurea to control the white count is usually allowed up to the first study dose.
FLT3 Inhibitors
Rydapt (midostaurin), Xospata (gilteritinib), Vanflyta (quizartinib) — trials of newer FLT3 drugs or FLT3 combinations frequently exclude prior gilteritinib or quizartinib, or cap the number of prior FLT3 inhibitors, while prior midostaurin given with 7+3 is often permitted. Because these drugs and many study drugs prolong the QT interval, protocols also set a QTcF limit (commonly 450 to 480 msec) at screening.
IDH and Menin Inhibitors
Tibsovo (ivosidenib), Rezlidhia (olutasidenib), Idhifa (enasidenib), Revuforj (revumenib), Komzifti (ziftomenib) — studies of a drug in the same class usually exclude people who have already taken one, and frontline menin inhibitor trials (KOMET-017, REVEAL-ND, cAMeLot-2) require no prior treatment for AML at all. Protocols typically require that any earlier differentiation syndrome has fully resolved.
Azole Antifungals and Other CYP3A Drugs
posaconazole, voriconazole, fluconazole, isavuconazole (Cresemba), clarithromycin — these are not reasons for exclusion, but most AML study drugs are cleared by CYP3A4 and the protocol will either lower the study drug dose or ask your team to switch antifungals. Tell the study team about every antifungal, antibiotic and antiviral you take, because the dose tables depend on them.
Steroids, Hydroxyurea and Transfusion Support
dexamethasone, prednisone, hydroxyurea, growth factors (filgrastim), transfusions — short steroid courses for differentiation syndrome, hydroxyurea for a high white count, and transfusions are allowed in nearly every AML trial, often right up to the first dose. Growth factors are usually paused around response assessments so that they do not confuse the count recovery that defines remission.
Post-Transplant Medicines
tacrolimus, cyclosporine, sirolimus, Jakafi (ruxolitinib), Rezurock (belumosudil) — trials for relapse after a transplant usually require that you are off immune suppression, or on a stable low dose, and have no active graft-versus-host disease of a set grade. Maintenance trials after transplant have their own windows, often starting 30 to 100 days after the transplant.
Timing matters more than any single medicine
Most AML trials are built around a treatment moment: newly diagnosed and untreated, first relapse, or remission after a set number of cycles. Once you take the first dose of standard therapy, many frontline trials close to you. If a trial interests you, ask your leukemia doctor to check it before treatment starts, even if that means a day or two of delay that your doctor judges safe.
A conflict does not always mean you cannot join
Many conflicts come with a washout period, often 14 days or 5 half-lives for pills and 4 weeks for antibodies, after which you may qualify. Whether a pause is safe depends on how active the leukemia is, so this is always a decision with your hematologist, and hydroxyurea is usually allowed to hold the white count during the gap.
Supportive care is almost always allowed
Antibiotics, antivirals, anti-nausea medicines, transfusions and pain medicines rarely appear in exclusion criteria. When the checker flags an antifungal, the excerpt is usually about dose adjustment of the study drug rather than exclusion; read the text carefully and bring it to the study coordinator.
Do not see your medication listed?
The checker covers the medicines most relevant to AML trials: leukemia treatments, antifungals, post-transplant immune suppression and common supportive medicines. If yours is not in the list, we have not found it commonly named in AML trial criteria. The study coordinator can confirm it against the protocol.
How the medication conflict checker works: This free tool helps people with acute myeloid leukemia learn whether their current medications could affect clinical trial eligibility. It scans the published eligibility criteria of active AML trials on ClinicalTrials.gov and flags which ones may exclude or restrict your treatment. Matches are grouped by confidence: high confidence means the trial names your exact drug, medium means it names the drug class, and low means the wording could apply to you. It is a starting point for a conversation with your leukemia team, not a determination of eligibility.
Across 1,853 open rare disease treatment trials, a third exclude people over a medication they commonly take. See which medications and diseases, in our September 2026 analysis.
Sources: Drug classes and warnings come from the FDA prescribing information for each medicine (openFDA, read October 19, 2026); washout and timing patterns are summarized from the eligibility criteria of AML trials registered on ClinicalTrials.gov and vary by trial.